Disease state of individuals who are seropositive for antibodies to HIV can be monitored and predicted by intermittently determining the level of HIV p17 and/or free complexing anti-p17 antibody in a body fluid. Levels of HIV p24 and free complexing anti-p24 can be simultaneously determined for information of maximum prognostic significance. Level of p17 can be measured by means of a heterogeneous sandwich ELISA. Level of anti-p17 antibody can be measured by means of a binding capacity assay using the same ELISA and exogenous p17.
展开▼